ECM
CRBU icon

ExodusPoint Capital Management’s Caribou Biosciences CRBU Stock Holding History

ExodusPoint Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-77,704
Closed -$124K – 1638
2025
Q4 		$124K Buy
+77,704
New +$163K ﹤0.01% 1424
2024
Q2 		– Sell
-158,612
Closed -$815K – 1594
2024
Q1 		$815K Buy
+158,612
New +$978K 0.01% 1009
2023
Q3 		– Sell
-39,350
Closed -$167K – 1764
2023
Q2 		$167K Buy
+39,350
New +$177K ﹤0.01% 1704
2022
Q3 		– Sell
-54,344
Closed -$295K – 1938
2022
Q2 		$295K Buy
+54,344
New +$415K ﹤0.01% 1546

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ExodusPoint Capital Management's CRBU Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Caribou Biosciences (CRBU) in Q1 2026, closing a stake of 77,704 shares — an estimated $124K sold.

ExodusPoint Capital Management first reported a position in CRBU in Q2 2022 and held it in 4 quarters. The position peaked at $815K in Q1 2024. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • ExodusPoint Capital Management reported no remaining Caribou Biosciences position as of Q1 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 77,704 Caribou Biosciences shares in Q1 2026, an estimated $124K.
  • ExodusPoint Capital Management first reported a position in Caribou Biosciences in Q2 2022 and held it in 4 quarters.
  • ExodusPoint Capital Management's Caribou Biosciences position peaked at $815K in Q1 2024.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.